{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:28:09Z","timestamp":1791725289968,"version":"4.3.4"},"reference-count":12,"publisher":"Walter de Gruyter GmbH","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2020-0260_abs_001_w2aab3b7c17b1b6b1aab1c16b1Aa\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Osteogenesis imperfecta type VI (OI VI) follows a progressive and severe course, yet unlike other forms of severe OI it has a later onset of fractures, and extra-skeletal findings are not part of the clinical picture. Another difference is that there is an increase in unmineralized osteoid tissue in OI VI, which hinders the effect of bisphosphonates-the current standard of treatment for OI. Therefore, the response to standard treatments in OI VI is not satisfactory. Herein, we report long-term follow-up of two cases with novel <jats:italic>SERPINF1<\/jats:italic> mutations, who show great variation in their treatment response to bisphosphonates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0260_abs_002_w2aab3b7c17b1b6b1aab1c16b2Aa\">\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>The first case was given pamidronate at the age of 15 months when he could sit independently, followed a fluctuating course under treatment, fracture rate did not decrease, however he was able to mobilize with walker at the age of 10 years. On the other hand, the second case developed severe deformities and became wheelchair-bound under pamidronate, thus the treatment was switched to denosumab. Unfortunately, there was no improvement under denosumab after 15 months too, and since bone pain increased, denosumab treatment was stopped. He was put on zoledronic acid instead.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0260_abs_003_w2aab3b7c17b1b6b1aab1c16b3Aa\">\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>\n                     <jats:italic>SERPINF1<\/jats:italic> transcript amount may be an important factor to explain the variation in response to pamidronate therapy. In OI VI patients, the factors affecting the clinical course should be identified and new or combined treatment options should be established.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2020-0260","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T23:48:48Z","timestamp":1602373728000},"page":"1617-1624","source":"Crossref","is-referenced-by-count":3,"title":["Treatment response to long term antiresorptive therapy in osteogenesis imperfecta type VI: does genotype matter?"],"prefix":"10.1515","volume":"33","author":[{"given":"Nur Berna","family":"Celik","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli","family":"Gonc","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev","family":"Ozon","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayfer","family":"Alikasifoglu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[{"name":"Genetics Unit , Shriners Hospital for Children and McGill University , Montr\u00e9al , Qu\u00e9bec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurgun","family":"Kandemir","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Hacettepe University Medical School , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"2023040101094790626_j_jpem-2020-0260_ref_001_w2aab3b7c17b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Glorieux, FH, Ward, LM, Rauch, F, Lalic, L, Roughley, PJ, Travers, R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002;17:30\u20138. https:\/\/doi.org\/10.1359\/jbmr.2002.17.1.30.","DOI":"10.1359\/jbmr.2002.17.1.30"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_002_w2aab3b7c17b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Homan, EP, Rauch, F, Grafe, I, Lietman, C, Doll, JA, Dawson, B, et al. Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res 2011;26:2798\u2013803. https:\/\/doi.org\/10.1002\/jbmr.487.","DOI":"10.1002\/jbmr.487"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_003_w2aab3b7c17b1b6b1ab2b1b3Aa","unstructured":"Semler, O, Netzer, C, Hoyer-Kuhn, H, Becker, J, Eysel, P, Schoenau, E. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 2012;12:183\u20138."},{"key":"2023040101094790626_j_jpem-2020-0260_ref_004_w2aab3b7c17b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Hoyer-Kuhn, H, Netzer, C, Koerber, F, Schoenau, E, Semler, O. Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis 2014;9:145. https:\/\/doi.org\/10.1186\/s13023-014-0145-1.","DOI":"10.1186\/s13023-014-0145-1"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_005_w2aab3b7c17b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Ward, L, Bardai, G, Moffatt, P, Al-Jallad, H, Trejo, P, Glorieux, FH, et al. Osteogenesis imperfecta type VI in individuals from Northern Canada. Calcif Tissue Int 2016;98:566\u201372. https:\/\/doi.org\/10.1007\/s00223-016-0110-1.","DOI":"10.1007\/s00223-016-0110-1"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_006_w2aab3b7c17b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Trejo, P, Palomo, T, Montpetit, K, Fassier, F, Sato, A, Glorieux, FH, et al. Long-term follow-up in osteogenesis imperfecta type VI. Osteoporos Int 2017;28:2975\u201383. https:\/\/doi.org\/10.1007\/s00198-017-4141-x.","DOI":"10.1007\/s00198-017-4141-x"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_007_w2aab3b7c17b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Becker, J, Semler, O, Gilissen, C, Li, Y, Bolz, HJ, Giunta, C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011;88:362\u201371. https:\/\/doi.org\/10.1016\/j.ajhg.2011.01.015.","DOI":"10.1016\/j.ajhg.2011.01.015"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_008_w2aab3b7c17b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Tucker, T, Nelson, T, Sirrs, S, Roughley, P, Glorieux, FH, Moffatt, P, et al. A co-occurrence of osteogenesis imperfecta type VI and cystinosis. Am J Med Genet A 2012;158a:1422\u20136. https:\/\/doi.org\/10.1002\/ajmg.a.35319.","DOI":"10.1002\/ajmg.a.35319"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_009_w2aab3b7c17b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Venturi, G, Gandini, A, Monti, E, Dalle Carbonare, L, Corradi, M, Vincenzi, M, et al. Lack of expression of SERPINF1, the gene coding for pigment epithelium-derived factor, causes progressively deforming osteogenesis imperfecta with normal type I collagen. J Bone Miner Res 2012;27:723\u20138. https:\/\/doi.org\/10.1002\/jbmr.1480.","DOI":"10.1002\/jbmr.1480"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_010_w2aab3b7c17b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Al-Jallad, H, Palomo, T, Roughley, P, Glorieux, FH, McKee, MD, Moffatt, P, et al. The effect of SERPINF1 in-frame mutations in osteogenesis imperfecta type VI. Bone 2015;76:115\u201320. https:\/\/doi.org\/10.1016\/j.bone.2015.04.008.","DOI":"10.1016\/j.bone.2015.04.008"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_011_w2aab3b7c17b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Miller, JN, Pearce, DA. Nonsense-mediated decay in genetic disease: friend or foe? Mutat Res Rev Mutat Res 2014;762:52\u201364. https:\/\/doi.org\/10.1016\/j.mrrev.2014.05.001.","DOI":"10.1016\/j.mrrev.2014.05.001"},{"key":"2023040101094790626_j_jpem-2020-0260_ref_012_w2aab3b7c17b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Holbrook, JA, Neu-Yilik, G, Hentze, MW, Kulozik, AE. Nonsense-mediated decay approaches the clinic. Nat Genet 2004;36:801\u20138. https:\/\/doi.org\/10.1038\/ng1403.","DOI":"10.1038\/ng1403"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/jpem\/33\/12\/article-p1617.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0260\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0260\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T18:33:14Z","timestamp":1680373994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0260\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":12,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,10,9]]},"published-print":{"date-parts":[[2020,12,16]]}},"alternative-id":["10.1515\/jpem-2020-0260"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2020-0260","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,8]]}}}